Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
  • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
  • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• compositions comprising a combination of calcitriol and a clobetasol propionate
• the present invention relates to pharmaceutical compositions in the form of a gel, a cream, a lotion, a solution or an ointment comprising, in a pharmaceutically acceptable medium, at least calcitriol and clobetasol propionate, and to the use of those compositions for the preparation of a medicinal product for treating dermatological complaints such as psoriasis, atopic dermatitis, contact dermatitis and seborrhoeic dermatitis.
• the invention relates to pharmaceutical compositions comprising at least calcitriol and clobetasol propionate, in a given ratio such that a synergistic effect between the two active principles is observed in the treatment of dermatological complaints such as psoriasis, atopic dermatitis, contact dermatitis and seborrhoeic dermatitis .
• the combination of active principles is not used conventionally in the treatment of dermatological complaints. This is generally due to the difficulty encountered by a person skilled in the art during the combination of two active principles as regards the chemical stability and the interactions that the medicinal products may present when they are present in the same formulation.
• Calcitriol is a vitamin D analogue used to regulate the level of calcium in the body.
• compositions comprising calcitriol that may also contain an amount of an antiinflammatory agent such as clobetasol propionate; however, no concrete embodiment for combining calcitriol and a corticosteroid is described or tested in terms of efficacy. Consequently, it was not obvious to a person skilled in the art to anticipate that the combination of calcitriol with clobetasol propionate would have any synergistic effect .
• WO 00/64450 mentions the use of a pharmaceutical composition containing a vitamin D analogue and clobetasol propionate.
• compositions in the said patent application combine calcipotriol and betamethasone .
• the comparison of the measurements of the efficacy, on patients suffering from psoriasis of a composition comprising calcipotriol alone, betamethasone alone or a combination of the two active agents shows that the effect obtained by the combination corresponds to an additive effect.
• a person skilled in the art could not in any way have imagined that the combination of a vitamin D analogue with a cortico- steroid could have a synergistic effect.
• the Applicant has discovered, surprisingly, that the combination of calcitriol with clobetasol propionate affords a synergistic effect in the treatment of certain dermatological complaints such as psoriasis, atopic dermatitis, contact dermatitis and seborrhoeic dermatitis.
• the present invention relates to a pharmaceutical composition in the form of a gel, a cream, a lotion or a solution for topical use, comprising, in a pharmaceutically acceptable medium: a) calcitriol, and b) clobetasol propionate.
• the calcitriol and the clobetasol propionate are present in the composition according to the invention in an amount such that they act synergistically to give the composition a therapeutic effect higher than the theoretical effect obtained by adding together the effects obtained by each of the two active agents taken separately.
• clobetasol propionate low doses of clobetasol propionate are sufficient to have an effective action when it is used in combination with calcitriol, for example, the use of 0.01% of clobetasol propionate results in a reduction of inflammation when it is combined with 0.0003% of calcitriol ( Figure 2), whereas clobetasol propionate alone at this concentration shows moderate efficacy ( Figures 1 and 2) .
• the calcitriol may be used at concentrations of between 0.0001 and 1 mg/g of composition.
• the compositions are gels, creams, lotions or solutions and contain clobetasol propionate at concentrations of between 0.01% and 2% by weight relative to the total weight of the composition.
• Another subject of the invention relates to a pharmaceutical composition containing calcitriol, advantageously at concentrations of between 0.001 to 1 mg/g of composition, and 0.01% of clobetasol propionate by weight relative to the total weight of the composition.
• the composition as previously described is an ointment, a cream, a lotion a solution or a gel, advantageously an ointment.
• the compositions according -to the present invention are thus formulated either in the form of creams, lotions, solutions or gels, or in the form of ointments by using a suitable vehicle.
• the creams may be formed from a mixture of mineral oil, or a mixture of beeswax and water that emulsifies instantaneously, to which is added the calcitriol, dissolved in a small amount of oil such as almond oil.
• the lotions may be prepared by dissolving the calcitriol and the clobetasol propionate in an alcohol of high molecular mass, such as polyethylene glycol.
• the ointments may be formulated by mixing together a solution of calcitriol and of clobetasol propionate in an oil such as almond oil, in heated paraffin, followed by allowing the mixture to cool.
• the gels may preferably be prepared by dispersing or dissolving the calcitriol and the clobetasol propionate in a suitable ratio, in a gel of carbomer, poloxamer or cellulosic type.
• Topical composition containing preserving agents, for example DL- ⁇ -tocopherol, or fragrances, if necessary.
• preserving agents for example DL- ⁇ -tocopherol, or fragrances, if necessary.
• the present invention also relates to one of the pharmaceutical compositions as defined above, characterized in that it shows a synergistic effect between calcitriol and clobetasol propionate in the treatment of dermatological complaints such as psoriasis, atopic dermatitis, contact dermatitis and seborrhoeic dermatitis.
• the present invention also relates to the use of one of the compositions as defined above for the manufacture of a medicinal product for treating dermatological complaints such as psoriasis, atopic dermatitis, contact dermatitis and seborrhoeic dermatitis, advantageously psoriasis.
• the invention also relates to the use of a pharmaceutical composition in the form of an ointment for topical use comprising, in a pharmaceutically acceptable medium: a) calcitriol, and b) clobetasol propionate for the manufacture of a medicinal product for treating atopic dermatitis, contact dermatitis and seborrhoeic dermatitis .
• compositions of the invention offer the following advantages over the prior art, in the case of treatment of skin complaints: - a composition containing a combination of calcitriol and clobetasol propionate will have the advantage of having better efficacy than the use of calcitriol alone, the use of a combination of clobetasol propionate and calcitriol makes it possible to shorten the treatment period, a composition containing a mixture of calcitriol and topical clobetasol propionate, such as clobetasol propionate, makes it possible to use a lower dose of calcitriol, and thus to reduce the side effects of calcitriol (irritation and hypercalcaemia) and also the risks associated with the use of corticosteroids, in particular immune deficiency and functional modifications of the HPA axis (hypothalamo-pituitary-adrenal axis) , the use of a combination of calcitriol and clobetasol propionate reduces the side effects of
• Figure 1 Dose-response effect of the topical application of clobetasol propionate (product B) on the intensity of mouse ear oedema. The results expressed are the average of seven mice (+ SD (standard deviation) ) . The statistical value was determined using Student's t test (NS: non- significant p > 0.05; ***p ⁇ 0.001).
• Figure 2 Synergistic effect produced by the application of a combination of calcitriol (product A) and clobetasol propionate (product B) on mouse ear oedema .
• Figure 4 Synergistic effect produced by the application of a combination of calcitriol (product A) and clobetasol propionate (product B) on the count of ganglionic cells.
• Figure 5 Synergistic effect produced by the application of a combination of calcitriol (product A) and clobetasol propionate (product B) on the cutaneous concentration of IFN- ⁇ .
• Example 1 Model of mice sensitized with a hapten
• calcitriol is denoted as product A and clobetasol propionate as product B.
• mice 8-week-old Balb/c mice are pretreated on the abdominal skin from day 1 to day 6 using product A or B, or A and B diluted in ethanol.
• the mice are actively sensitized by the topical application of 50 mg of oxazolone (oxa) in ethanol onto the abdominal skin.
• an application of 20 mg of oxa in ethanol is performed on the right ear.
• the thickness of the ear is measured, using a micrometer, on day 11 (just before the application of oxazolone to the presensitized mice) and after 24 hours, on day 12.
• the ear oedema is expressed as the difference between the measurement of the thickness of the ear between day 12 and day 11.
• the values of the thickness of the ear are analysed statistically using Student's t test.
• the experimental results show a dose- response effect for product ( Figure 1).
• the 0.01% dose was chosen to perform the treatment using the combination of product A and product B, in order to be able to observe a synergistic effect.
• Figure 2 shows a synergistic effect during the use of a combination of product A with product B. l.B. Count of the ganglionic cells:
• FIG. 1 shows a dose-response effect for product B. The 0.01% dose was chosen to perform the treatment using the combination of product A and product B, in order to be able to observe a synergistic effect.
• Figure 4 shows a synergistic effect during the use of a combination of product A with product B.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Dermatology (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (8)

Applications Claiming Priority (4)

Related Child Applications (1)

Publications (1)

Family

ID=32598899

Family Applications (1)

Country Status (13)

Cited By (6)

Families Citing this family (3)

Citations (3)

Family Cites Families (2)

• 2003
  • 2003-12-11 PL PL03374777A patent/PL374777A1/xx not_active Application Discontinuation
  • 2003-12-11 JP JP2004560485A patent/JP2006511545A/ja active Pending
  • 2003-12-11 EP EP03789441A patent/EP1575598B8/en not_active Revoked
  • 2003-12-11 KR KR1020057011398A patent/KR20050085787A/ko not_active Application Discontinuation
  • 2003-12-11 AU AU2003294027A patent/AU2003294027B2/en not_active Ceased
  • 2003-12-11 WO PCT/EP2003/015011 patent/WO2004054588A1/en active IP Right Grant
  • 2003-12-11 AT AT03789441T patent/ATE374614T1/de not_active IP Right Cessation
  • 2003-12-11 CA CA002505406A patent/CA2505406A1/en not_active Abandoned
  • 2003-12-11 RU RU2005122466/15A patent/RU2361594C2/ru not_active IP Right Cessation
  • 2003-12-11 BR BR0315195-6A patent/BR0315195A/pt not_active IP Right Cessation
  • 2003-12-11 DE DE60316724T patent/DE60316724T2/de not_active Revoked
  • 2003-12-11 MX MXPA05003805A patent/MXPA05003805A/es active IP Right Grant
• 2005
  • 2005-06-17 US US11/154,706 patent/US20060009426A1/en not_active Abandoned

Patent Citations (3)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events